Загрузка...
The growing landscape of FLT3 inhibition in AML
Midostaurin and gilteritinib are FLT3 inhibitors that have been recently approved for use in FLT3-mutant acute myeloid leukemia (AML). These approved drugs represent a new standard of care for patients with FLT3 mutations in both the first-line and salvage settings. The success of midostaurin used i...
Сохранить в:
| Опубликовано в: : | Hematology Am Soc Hematol Educ Program |
|---|---|
| Главный автор: | |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
American Society of Hematology
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6913436/ https://ncbi.nlm.nih.gov/pubmed/31808872 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2019000058 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|